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Methodological quality and reporting of
ethical requirements in clinical trials
Miguel Ruiz-Canela, Jokin de Irala-Estevez, Miguel Ángel Martínez-González, Enrique Gómez-Gracia and
Joaquín Fernández-Crehuet University of Navarre and University of Malaga, Spain
Abstract
Objectives—To assess the relationship between the
approval of trials by a research ethics committee
(REC) and the fact that informed consent from
participants (ICP) was obtained, with the quality of
study design and methods.
Design—Systematic review using a standardised
checklist.
Main measures—Methodological and ethical issues of
all trials published between 1993 and 1995 in the
New England Journal of Medicine, the Lancet, the
Journal of the American Medical Association and
the British Medical Journal were studied. In
addition, clinical trials conducted in Spain and
published by at least one Spanish author during the
same period in any other journal were also included.
Results—We studied the published articles of 767
trials and found the following indicators of lower
methodological quality to be independent predictors for
failure to disclose REC approval or ICP: absence of
concealment of allocation, lack of justification for
unblinded trials, not using a treatment for the patients
in the control group, absent information on statistical
methods, not including sample size estimation, not
establishing the rules to stop the trial, and omitting the
presentation of a baseline comparison of groups
Conclusion—Trials of higher methodological and
scientific quality were more likely to provide
information about their ethical aspects.
(Journal of Medical Ethics 2001;27:172–176)
Keywords: Clinical trials; informed consent; research eth-
ics committees; research design
Introduction
Methodological quality is the first ethical require-
ment in clinical trials.1 Moreover, the approval of a
research ethics committee (REC) and obtaining
informed consent from patients (ICP) could be
considered the main issues in the ethics of research
with human beings.2
Both methodological and ethical aspects should
be adequately reported to enable readers to make an
accurate assessment of the clinical research about
which they are reading.3 4 However, there are several
studies that have found deficiencies in reporting the
design and conduct of trials.5–10 It has also been
shown that disclosure of the ICP and REC approval
in published reports is sometimes incomplete, and
sometimes omitted.11–19 Nevertheless, very few stud-
ies have assessed the relationship between omission
of REC or ICP and methodological quality of trials.
We present the main results of a systematic
evaluation of 767 clinical trials where the disclosure
of REC approval and ICP was assessed, as well as the
association between reporting these aspects and the
methodological quality of the trials.
Methods
Two short preliminary reports, including some of
our methods, have been published elsewhere.17 20
They addressed diVerent issues from the present
study. A standardised protocol was applied for
reviewing every article of trials published between
1993-1995 in the New England Journal of Medicine,
the Lancet, the Journal of the American Medical
Association, and the British Medical Journal. To
identify eligible articles, all issues of these journals
were hand-searched. In addition, the MEDLINE
bibliographic database (1993-1996) was used to
identify all trials published in other journals during
1993-1995 by at least one Spanish author, for the
purpose of evaluating clinical trials conducted in
our country. We included every publication of
experimental trials on humans that had two or
more study groups21 and all studies labelled as
“clinical trials”, “field trials” or “randomised trials”
by the authors. The exclusion criteria were: 1) non-
experimental (observational) studies; 2) studies
assessing a diagnostic test to estimate its sensitivity,
specificity or other validity measures; 3) trials pub-
lished as letters to the editor or short articles, and 4)
secondary analyses of previously published studies.
The standardised protocol for assessing each trial
and the process of data collection were based on a
checklist (available from authors) that was con-
structed after reviewing 43 previously published
checklists.22 After a pilot study, the selection of
items to be included was performed with the help of
an ad hoc expert panel. Some of the items selected
were: year of publication; type of outcome to be
assessed and end point(s) of the trial; number of
centres participating in the study; country(ies) of
origin; specialty of authors; source of funding;
number of patients whose participation was re-
quested; number of randomised participants; meth-
ods used to generate the allocation scheme and
method for concealment of allocation; baseline
comparison of groups; whether a hypothesis test
was used in this comparison (hypothesis testing
being inappropriate to exclude confounding23;) type
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of treatment and control; blinding in the assess-
ment of outcomes; justification of opened (un-
blinded) trials; information on statistical methods;
sample size estimation; rules and monitoring to
stop the trial after interim analyses, and disclosure
of REC approval and ICP.
When information on REC approval or ICP was
missing in an article, we sent the corresponding
authors a standardised questionnaire enquiring
whether the trial had in fact been approved by an
REC and whether the participants had provided
informed consent. If the response was negative, we
requested an explanation as to why REC approval
or ICP was not obtained. After two months, we
repeated the mailing to those who had not replied.
For each trial, one of us (MRC) completed the
evaluation of all relevant aspects of trial design,
methods and ethical issues. Another researcher
(MAM) independently re-evaluated a randomly
selected sample of 30 trials while blinded to the
results of the first assessment. The between-raters
agreement was assessed by computing the kappa
index. In the subsequent evaluation, any doubt as to
how to classify an item was discussed between the
investigators mentioned above. Items with a kappa
index less than 0.35 were not used in subsequent
analyses.
A multivariable logistic regression model was
fitted to assess the methodological characteristics
independently related to disclosing those ethical
requirements (REC/ICP). In this model, we
considered the failure to report that either REC
or ICP had been obtained, or the explicit
disclosure in the original paper that any of these
requirements were not obtained, as the outcome.
Multivariable analysis was performed with the aim
of controlling for several variables that could be
considered as potential confounders. In addition,
we considered all indicators of methodological
quality with a p value <0.25 in the univariate
analysis as candidate variables for the multivari-
able model. After including these potential predic-
tors and/or confounders in one multivariable
model, the final model was obtained by gradually
removing non-significant variables using the likeli-
hood ratio test and by evaluating potential
confounding with the criterion of a 10% change
between crude and adjusted estimates of the odds
ratios.
Our study was not approved by an REC, nor did
we request informed consent from the authors of
the articles because our research did not involve an
experimental design using human beings.
Table 1 Characteristics of the trials associated with not reporting any or both ethical issues (REC approval and/or request of
informed consent from participants). Logistic regression analysis. Odds ratios (OR) and 95 per cent confidence intervals (CI)
Quality indicators (number of trials)
Proportion not
reporting request
of ICP
Proportion not
reporting REC
approval
Proportion not
reporting both
request of ICP and
REC approval
Adjusted OR*
(95% CI)
All sample (767) 19.8 29.2 12.9
Concealment of allocation
Yes (264)† 14.8 24.2 8.0 1 (ref)‡
No (503) 22.5 31.8 15.5 1.66 (1.12–2.46)
Justification of unblinded trials
Yes (36)† 8.3 19.4 5.6 1 (ref)‡
No (280) 26.1 41.1 18.2 2.70 (1.09–6.66)
Type of treatment for control group
Placebo (273)† 11.7 18.7 7.0 1 (ref)‡
Alternative active treatment (366) 21.3 33.6 14.5 1.39 (0.88–2.20)
No treatment (105) 35.2 40.0 21.9 2.47 (1.37–4.47)
Not a proper control group (23) 21.7 34.8 17.4 1.75 (0.52–5.81)
Reporting of statistical methods
Yes: some information reported (739)† 18.9 27.9 12.0 1 (ref)§
No information about statistical methods (28) 42.9 64.3 35.7 3.77 (1.42–9.98)
Sample size estimation
Shown (320)† 14.4 23.1 6.9 1 (ref)‡
Not shown (447) 23.7 33.6 17.2 1.49 (1.02–2.19)
Rules to stop the trial
Reported (269)† 12.1 21.6 6.4 1 (ref)‡
Not reported (498) 23.7 32.9 16.3 1.33 (0.99–1.78)
Baseline comparison of groups
Presented (679)† 18.6 27.1 11.6 1 (ref)‡
Not presented (88) 29.5 45.5 22.7 1.80 (1.05–3.08)
Outcome
Survival (166)† 22.9 30.7 13.9 1 (ref)§
Other (601) 19.0 28.8 12.6 0.52 (0.33–0.84)
Trials that acknowledged that they did not obtain the REC (Research Ethics Committee) approval or the ICP (informed consent from par-
ticipants) are included together with those that did not disclose the information about these issues in the original report.
*A higher odds ratio (OR) means a higher probability of failing to provide information about either or both ethical issues in the original paper.
Odds ratios have been also adjusted for journal, country of authors, length of the report, number of participants and source of funding.
†This was the reference category (ref: reference category).
‡p<0.05 (Likelihood ratio test).
§p<0.01 (Likelihood ratio test).
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Results
A brief descriptive assessment of the proportion of
studies failing to report the ethical requirements
has been published elsewhere.17 Table 1 shows the
study quality indicators that were identified in the
multivariable analysis as independent predictors of
failure to report information about REC approval,
ICP, or both. In addition to the variables shown in
the table, the analysis was also adjusted for the
length of the article, the journal in which the article
was published, the country of authors, the number
of participants and the source of funding.
Once adjusted for the other variables, an open
randomisation procedure (failure to conceal alloca-
tion) was independently associated with not
presenting information on ICP and/or approval by
an REC. Among open trials, those that did not jus-
tify the unblinded assessment of the outcome were
more likely not to report ICP/REC. Trials which
did not use a treatment for the patients in the con-
trol group omitted this information significantly
more often. Not disclosing information on statisti-
cal methods, nor on sample size estimation; not
providing the rules to stop the trial, and not
presenting a comparison of the distribution of
baseline factors were characteristics independently
and more frequently associated with the omission
of ICP/REC. Trials with survival of patients as the
outcome were less likely to provide information
about these ethical issues.
When we fitted the logistic models using the
actual responses of authors to our queries (mailed
questionnaires) as the outcome, and reclassified the
authors who replied that they had in fact obtained
the ICP/REC in spite of not having reported it, the
adjusted odds ratios for most of the indicators of
lower quality remained high: no justification of
unblinded trials (OR=2.62); no information about
statistical methods (OR=1.62); omitting sample
size estimation (OR=1.34), and not reporting the
rules to stop the trial (OR=1.43).
When the two ethical issues were considered as
separate outcomes, all associations maintained the
same direction and most of them remained consist-
ent and statistically significant (see table 2).
Discussion
The hypothesis of this study was that the higher the
methodological and scientific quality of a trial, the
more attention was given to its ethical aspects. Our
findings suggest that, independently of the journal
where they were published and the length of the
report (among other descriptive variables), trials
with higher standards of quality met the requirement
of reporting ethical issues more frequently. Other
authors have previously assessed some of these
standards as indicators of quality (concealment of
allocation,6 sample size estimation,7 8 statistical meth-
ods,9 and justification of open trials,10) but have not
Table 2 Characteristics of the trials associated with not reporting either informed consent from participants or REC approval.
Separated logistic regression models for reporting of each ethical issue as the outcome. Adjusted odds ratios (OR) and 95 per cent
confidence intervals (CI)
Quality indicators
Not reporting informed consent Not reporting REC approval
Adjusted OR (95% CI) p† Adjusted OR* (95% CI) p†
Concealment of allocation <0.01 0.01
Yes‡ 1 (ref) 1(ref)
No 1.95 (1.19–3.18) 1.72(1.13–2.60)
Justification of unblinded trials 0.72 <0.01
Yes‡ 1 (ref) 1(ref)
No 1.09 (0.69–1.72) 1.75(1.16–2.64)
Type of treatment for control group <0.01 0.35
Placebo‡ 1 (ref) 1(ref)
No treatment 4.23 (2.15–8.31) 1.66(0.90–3.06)
Alternative active treatment 1.96 (1.13–3.39) 1.33(0.82–2.13)
Not a proper control group 2.59 (0.64–10.47) 1.93(0.58–6.42)
Reporting of statistical methods 0.09 0.01
Yes: some information reported‡ 1 (ref) 1(ref)
No information about statistical methods 2.13 (0.88–5.14) 2.96(1.24–7.03)
Sample size estimation <0.01 0.046
Shown‡ 1 (ref) 1(ref)
Not shown 1.94 (1.22–3.08) 1.50(1.01–2.23)
Rules to stop the trial 0.12 0.07
Reported‡ 1 (ref) 1(ref)
Not reported 1.21 (0.95–1.54) 1.24(0.98–1.57)
Baseline comparison of groups 0.36 0.03
Presented‡ 1 (ref) 1(ref)
Not presented 1.31 (0.74–2.32) 1.85(1.09–3.14)
Outcome <0.01 0.03
Survival‡ 1 (ref) 1(ref)
Other 0.41 (0.24–0.72) 0.59(0.37–0.95)
*Adjusted for journal, country of authors, length of the report, number of participants and source of funding.
†Likelihood ratio test.
‡This was the reference category (ref: reference category).
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related them to ethical aspects. Our results are con-
sistent with those of another study regarding the
association between lower quality and frequent
omission of reporting REC approval in studies
concerning cardiopulmonary resuscitation.
Nevertheless, the assessment of methodological
quality in that study was only based on the randomi-
sation scheme.14
The ethical requirements were not mentioned in
some articles, even though the authors responded
to our questionnaire that they had in fact requested
them. However, we chose the statements in the
original article (or lack thereof) over the actual
response of the authors, in terms of the information
provided on ICP requested or REC approval. This
decision was based on several reasons: a) This may
promote more reporting of ethical issues in
publications of clinical trials in the future; b) Some
authors did not respond to our questionnaires, and
therefore we could not ascertain what they had
actually done in their studies, and c) Failing to
report the ethical requirements in the original arti-
cle may already imply a lower concern for ethical
issues in trials.11 When we fitted the logistic model
using the actual responses of authors as the
outcome, the adjusted odds ratios for most of the
indicators of lower quality remained high. There-
fore, not only the actual reporting of ethical issues
in articles, but also the verified request for ICP or
REC approval, showed an association with higher
methodological quality.
We selected four journals that have had repre-
sentatives on the International Committee of
Medical Journal Editors (ICMJE) since its incep-
tion. This does not imply that these journals
consistently follow the uniform requirements in all
cases, but these are leading journals which publish
research reports in all fields and have a broad read-
ership. Medical journals which are published
weekly also provide a large enough sample to assess
the current trends in our topic of interest with pre-
cision. Reviewing trials with Spanish authors also
has some advantages because it provides a subset of
trials resembling a comparison (“pseudo-control”)
group. Most trials in this group were published in
specialised journals written in English.
Our results, in which trials with higher quality
standards were more likely to give attention to ethi-
cal aspects, are reassuring because readers could
consider these studies as models and examples of
good research. It is important to note that in certain
clinical trials, obtaining ICP may be more diYcult24
because of the patient’s condition (ie emergency
room or intensive care), or because the characteris-
tics of the intervention may be more suitable for
group rather than for individual randomisation (ie
schools randomised to usual care or a special nutri-
tion education programme). It is also possible that
trials with survival of patients as the outcome omit-
ted information about ICP/REC more often
because authors considered it was implicitly
assumed. However, the reasons why informed con-
sent and REC approval were or were not obtained
should always be stated.
Some authors have indicated the relevance and
importance of complete reporting, as well as the
importance of adequate methodological and ethical
quality of clinical trials.11 25 This reporting should
reflect both the weak and the strong aspects of
researchers’ work. It could be considered as
evidence of the concern for ethical aspects that
must be present not only during the conception,
design, and conduct of the research process,26 but
also in the publication and communication of
results.27 The association between methodological
quality and reporting of ethical requirements prob-
ably reflects the respect shown for patients during
the whole research process.
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